Primary report of the ziltivekimab cardiovascular outcomes trial (ZEUS)

Andreas Andersen; Florian Baeres; Kathrine Ekstroem; Mads Engelmann; Sofia Gerward; Kees Hovingh; Anders Hvelplund; Abraham Lincoff; Nikolaus Marx; Ann Marie Navar; Vlado Perkovic; Paul Ridker; Naveed Sattar; Lance Sloan; Lale Tokgozoglu; Katherine Tuttle

View all AHA 2026 trials

ZEUSPrevention

Primary report of the ziltivekimab cardiovascular outcomes trial (ZEUS)

What happened

Ziltivekimab cardiovascular outcomes from the ZEUS trial await presentation at AHA 2026.

Full evidence

Why the trial, key points, tables, limitations, PICO, abstract, media & sources

Ask AI

Bookmark

Discussion

1 take

Member takes

Synapse TeamOct 21

Ziltivekimab blocks IL-6 to go after residual inflammatory risk in patients with cardiovascular disease, chronic kidney disease and systemic inflammation. If ZEUS shows fewer major cardiovascular events, would you start checking hsCRP routinely in these patients — and who would you treat first?

Expert reaction

What experts said about ZEUS

AHA Scientific Sessions 2026

Cardiovascular prevention evidence still forming

0 experts have reacted so far. We show the split once 3 have.

Expert labels are toward ZEUS's result, from named public quotes (n=0). As of Oct 22, 2026.

Implication

Primary report of the ziltivekimab cardiovascular outcomes trial (ZEUS)

Abstract

Primary report of the ziltivekimab cardiovascular outcomes trial (ZEUS). Session: LBS.01. Late-breaking trial at AHA Scientific Sessions 2026. Results pending.

Cite This Study

Andersen et al. (2026) studied this question. Ziltivekimab cardiovascular outcomes from the ZEUS trial are currently pending presentation at the AHA Scientific Sessions 2026.

synapsesocial.com/papers/6ad94e21101c3306835df8be

Implication

Primary report of the ziltivekimab cardiovascular outcomes trial (ZEUS)

Abstract

Primary report of the ziltivekimab cardiovascular outcomes trial (ZEUS). Session: LBS.01. Late-breaking trial at AHA Scientific Sessions 2026. Results pending.